Market Overview

UPDATE: Piper Jaffray Reiterates Overweight Rating, Lowers PT on Achillion Pharmaceuticals

Share:
Related ACHN
18 Biggest Mid-Day Gainers For Friday
15 Stocks Moving In Friday's Pre-Market Session

In a report published Friday, Piper Jaffray & Co. reiterated its Overweight rating on Achillion Pharmaceuticals (NASDAQ: ACHN), but slightly lowered its price target from $17.00 to $16.00.

Piper Jaffray noted, “Achillion ended 2Q:12 with cash of $60 million and received gross proceeds of $41.8 million by issuing QVT 6.367 million shares at $6.57. Achillion has begun dosing HCV genotype 1 patients with NS5A inhibitor ACH-3102 with data in 3Q:12. We expect Achillion to begin Phase II combo trials with protease inhibitor sovaprevir by year-end with data in early 2013. Recent set-backs with Bristol-Myers' and Idenix's ‘nucs' benefit Achillion. We expect the wave of consolidation in HCV will continue with Achillion a likely target. We reiterate our Overweight rating and are trimming our target to $16 from $17 to account for dilution from the QVT deal.”

Achillion Pharmaceuticals closed on Thursday at $6.57.

Latest Ratings for ACHN

DateFirmActionFromTo
Sep 2016WedbushInitiates Coverage onOutperform
Sep 2016FBR CapitalInitiates Coverage onOutperform
Jul 2016Chardan CapitalInitiates Coverage onSell

View More Analyst Ratings for ACHN
View the Latest Analyst Ratings

Posted-In: Piper Jaffray & Co.Analyst Color Price Target Analyst Ratings

 

Related Articles (ACHN)

View Comments and Join the Discussion!